Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature

S. Di Bella, C. Nisii, N. Petrosillo

Research output: Contribution to journalArticle

Abstract

Clostridium difficile infection (CDI) has become the most frequent cause of nosocomial infectious diarrhoea in developed countries, causing an increase in mortality, recurrences or treatment failure. In the search for new and more effective drugs, researchers recently turned their attention to tigecycline, a broad-spectrum antibiotic of the glycylglycine class available as an intravenous formulation for human use, which has also shown in vitro activity against C. difficile. We performed a literature review of articles addressing in vitro as well as in vivo studies and case reports on the effectiveness of tigecycline, whose use is promising especially in light of its high faecal excretion. The available evidence suggests that tigecycline could play a role as an alternative therapeutic option for critically ill patients or cases of refractory CDI.

Original languageEnglish
JournalInternational Journal of Antimicrobial Agents
Volume46
Issue number1
DOIs
Publication statusPublished - Jun 8 2015

Keywords

  • CDI
  • Clostridium
  • Clostridium difficile
  • Clostridium difficile infection
  • Tigecycline

ASJC Scopus subject areas

  • Medicine(all)
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature'. Together they form a unique fingerprint.

  • Cite this